ReviewEuropean respiratory review : an official journal of the European Respiratory Society2024
Pathophysiology and genomics of bronchiectasis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- AI semantics for biomedical data integration.bioRxiv : the preprint server for biology · 2026Article
- Blood DNA methylation profile is altered in severe bronchiectasis.ERJ open research · 2026Article
- The frequent exacerbator phenotype in bronchiectasis revisited: data from EMBARC registry.American journal of respiratory and critical care medicine · 2026Article
- Risk of Obstructive Sleep Apnea in Patients with Emphysema Versus Bronchiectasis: A Propensity Score-Matched Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Natural Products Targeting Airway Inflammation and Mucus Hypersecretion: Molecular Mechanisms and Therapeutic Potential for Respiratory Health.Nutrients · 2026Review
- Integrative Multivariate Genomics Identifies Shared Epithelial-Immune and Cytokine-Regulatory Mechanisms Across Major Chronic Lung Diseases.International journal of molecular sciences · 2026Article
- Article
- Bronchiectasis in Inborn Errors of Immunity: Prevalence, Predictors, and Cardiopulmonary Complications in a Genetically Characterized Cohort.Journal of clinical immunology · 2026Observational
- Review
- Clinical phenotypes of secondary spontaneous pneumothorax (SSP) in different underlying lung diseases: a retrospective study and literature review on the clinical heterogeneity in this single entity.Journal of thoracic disease · 2026Article
- Fractional Exhaled Nitric Oxide in Children with Non-Cystic Fibrosis Bronchiectasis: Associations with Etiology, Lung Function, and CT Extent.Pediatric reports · 2026Article
- Bronchiectasis in Italy: an analysis of the EMBARC registry.ERJ open research · 2026Article
- Article
- The importance of symptoms in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Frequent exacerbators and neutrophil elastase activity in bronchiectasis: a network analysis approach.ERJ open research · 2026Article
- Distinct pulmonary pathophysiological mechanisms in COPD, bronchiectasis, and primary immunodeficiency: a multi-omics investigation of disease heterogeneity via sputum and blood profiling.Respiratory research · 2026Article
- Alpha-1 Antitrypsin Deficiency Beyond COPD and Emphysema: A Narrative Review.Medical sciences (Basel, Switzerland) · 2026Review
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is a complex and heterogeneous inflammatory chronic respiratory disease with an unknown cause in around 30-40% of patients. The presence of airway infection together with chronic inflammation, airway mucociliary dysfunction and lung damage are key components of the vicious vortex model that better describes its pathophysiology. Although bronchiectasis research has significantly increased over the past years and different endotypes have been identified, there are still major gaps in the understanding of the pathophysiology. Genomic approaches may help to identify new endotypes, as has been shown in other chronic airway diseases, such as COPD.Different studies have started to work in this direction, and significant contributions to the understanding of the microbiome and proteome diversity have been made in bronchiectasis in recent years. However, the systematic application of omics approaches to identify new molecular insights into the pathophysiology of bronchiectasis (endotypes) is still limited compared with other respiratory diseases.Given the complexity and diversity of these technologies, this review describes the key components of the pathophysiology of bronchiectasis and how genomics can be applied to increase our knowledge, including the study of new techniques such as proteomics, metabolomics and epigenomics. Furthermore, we propose that the novel concept of trained innate immunity, which is driven by microbiome exposures leading to epigenetic modifications, can complement our current understanding of the vicious vortex. Finally, we discuss the challenges, opportunities and implications of genomics application in clinical practice for better patient stratification into new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.